CytoDyn, Investors End Chancery Director Options Suit
Biotechnology company CytoDyn Inc. agreed to pay a $50,000 attorney fee in a Delaware Chancery Court settlement approved on Thursday that ended a stockholder challenge to excess stock options paid to...To view the full article, register now.
Already a subscriber? Click here to view full article